Company Overview - Plai Pharmaceuticals (Jiangsu) Co., Ltd. is a leading innovative antimicrobial peptide (AMP) therapeutic drug company established in April 2009, focusing on four core therapeutic areas: anti-infection, metabolic diseases, tumors, and autoimmune diseases [2] - The company has nine candidate drugs, including one core product (PL-5) and two major products (PL-3301 and PL-18) [2] - PL-5 is the first globally submitted new drug application (NDA) for a class of drugs known as cationic peptides, representing a novel mechanism of action to combat antibiotic resistance [2][3] Product Pipeline - PL-5 is entering the regulatory submission phase in China in 2024 and is undergoing Phase II clinical trials in the United States [3] - PL-3301 is a potential first-in-class temperature-sensitive peptide gel for treating oropharyngeal candidiasis, while PL-18 targets vulvovaginal candidiasis and may also treat various gynecological infections [3] - The company is expanding its pipeline to include treatments for metabolic diseases, tumors, and autoimmune diseases, with several assets in preclinical stages [3] Financial Performance - For the fiscal year 2024, the company reported revenues of approximately RMB 5.194 million, with a gross profit of about RMB 2.174 million [6][7] - The company recorded a net loss of approximately RMB 158.337 million for the fiscal year 2024, primarily due to research and development expenses and administrative costs [8] Industry Overview - The global peptide drug market is projected to grow from USD 62.8 billion in 2020 to USD 109.6 billion by 2024, with a compound annual growth rate (CAGR) of 5.8% expected from 2030 to 2035, reaching USD 288.5 billion [9] - The global anti-infection drug market is expected to reach USD 137.9 billion in 2024, with a slight decline anticipated by 2030, followed by a recovery to USD 145.7 billion by 2035 [11] - The peptide-based anti-infection drug market is projected to grow from USD 1.9 billion in 2024 to USD 5.7 billion by 2035, with a CAGR of 10.3% from 2024 to 2030 [14]

香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整 性亦不發表任何意見，並明確表示概不就因本申請版本全部或任何部分內容而產生或因倚賴該等內容而引 致的任何損失承擔任何責任。 ProteLight Pharmaceuticals (Jiangsu) Co., Ltd. 普萊醫藥（江蘇）股份有限公司 （「本公司」） （於中華人民共和國境內註冊成立的股份有限公司） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監會」）的 要求而刊發，僅用作提供資訊予香港公眾人士。 本申請版本為草擬本，其內所載資訊並不完整，亦可能會作出重大變動。 閣下閱覽本文件，即代 表 閣下知悉、接納並向本公司、本公司的獨家保薦人、整體協調人、顧問或包銷團成員表示同意： 倘於適當時候向香港公眾人士提出要約或邀請，有意投資者務請僅依據與香港公司註冊處處長註冊的 本公司招股章程作出投資決定；招股章程的文本將於發售期內向公眾人士提供。 (a) 本文件僅為向香港公眾人士提供有關本公司的資料，概無任何其他目的；投資者不應根據本文 件中的資料作出任何投資決定； ...